DPP4 and plasma cell myeloma: Our findings also confirmed that isoform-selective (class I or class IIb) HDACi plus CD26mAb in combination may induce synergistic cytotoxicity against myeloma cells via the upregulation of CD26 on myeloma cells and enhanced ADCC activity by CD26mAb.